Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients

Cancer immunotherapy, including atezolizumab monotherapy, is a promising alternative strategy for patients with advanced non-small-cell lung cancer (NSCLC). Several inflammatory indices have been reported as potential biomarkers regarding the effectiveness of various treatments. This study aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Katayama, Yuki, Yamada, Tadaaki, Chihara, Yusuke, Tanaka, Satomi, Tanimura, Keiko, Okura, Naoko, Hirose, Kazuki, Uda, Sayaka, Shiotsu, Shinsuke, Hirai, Soichi, Hiranuma, Osamu, Harada, Taishi, Shimamoto, Takayuki, Iwasaku, Masahiro, Kaneko, Yoshiko, Uchino, Junji, Takeda, Takayuki, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566597/
https://www.ncbi.nlm.nih.gov/pubmed/33060826
http://dx.doi.org/10.1038/s41598-020-74573-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566597/
https://www.ncbi.nlm.nih.gov/pubmed/33060826
http://dx.doi.org/10.1038/s41598-020-74573-0

Ejemplares similares